20th Anniversary of the Dubrovnik Leukemia Meeting

SATELLITE SYMPOSIA

• Satellite Symposium I: Tyrosine kinase inhibitors
• Satellite Symposium II: Therapy of antifungal infections in immunocompromised patients
• Satellite Symposium III: Monoclonal Antibodyes in the treatment of Leukemia /Lymphoma
• Satellite Symposium IV: Prevention of antifungal infections in immunocompromised patients
• Satellite Symposium V: Aplastic anemia and related disorders
• Satellite Symposium VI: to be announced

OPENING CEREMONY AND PRESIDENTIAL SYMPOSIUM

• Emil Freireich, USA: Treatment of acute leukemia: 50 years later
• Elliane Gluckman, France: Cord blood transplantation for leukemia and lymphoma
• Dieter Hoelzer, Germany: Should we treat ALL as one disease?

CONCERT AND WELCOME COCKTAIL

Sunday 16.09. 2007.

SYMPOSIUM AML – Risk adapted therapy

• Clara D. Bloomfield, USA: Biology, cytogenetics, and molecular studies in AML
• Bob Lowenberg, The Netherlands: DNA microarray for diagnosis of AML
• Charles A. Schiffer,USA: Anything better than 3+7 for induction therapy?
• Roel Willemze, The Netherlands: Therpy for AML – AML 12 EORTC/Gimema trial
• Allan Burnett, United Kingdom: Therapy for acute myeloid leukemia - results of the UK MRC AML trials
• Ching-Hong Pui, USA: AML in children – current treatment approach
• Sergio Amadori,Italy: Therapy for elderly AML: The EORTC/GIMMEMA experience
• Miguel A. Sanz, Spain: Current Therapy for APL
• Didier Blaise, France: Reduced intensity conditioning for AML
• Francis Giles, USA: Novel agents for AML

Lunch /Lunch Symposium/
SYMPOSIUM MDS/MYELODYSPLASTIC SYNDROME/

• Peter L. Greenberg, USA: Prognostic scoring system in MDS
• Luca Malcovati, Italy: Transfusion dependence and iron overload in prognostic modelling of MDS
• Eva Hellstrom-Lindberg, Sweden: Low-risk MDS – do we need more than suportive care?
• Mickael Lübbert, Germany: To be announced
• Theo de Witte, The Netherlands: Stem cell transplantation for MDS
• Alan F. List, USA: New agents in the treatment of MDS

End of the day: East and West together (AML/MDS)

• Francis Giles, USA: AML: Current therapy, future trends
• Jiri Hollowiecki, Poland: Autotransplantation in AML: Polish treatment approach
• Hagop M. Kantarjian, USA: MDS: Current therapy, future trends
• Martin Mistrik, Slovakia: AML/MDS: How to proceed

Monday 17.09. 2007.

SYMPOSIUM CML/MYELOPROLIFERATIVE DISORDERS/

• Moshe Talpaz, USA: CML – current status of imatinib as therapy for CML & monitoring the response
• Jane Apperley, United Kingdom: Stem cell transplant for CML – with or without tyrosine kinase inhibitors.
• Jorge Cortes,USA: Drug resistance in CML
• Michele Baccarani,Italy: Nilotinib in CML
• Hagop M. Kantarjian, USA: Dasatinib in CML
• Ticiano Barbui, Italy: Polycythaemia vera
• A.R. Green, United Kingdom: Essential thrombocythaemia
• Ayalew Tefferi, USA: Myelofibrosis
• Srdan Verstovsek, USA: New therapeutic agents for Myeloproliferative disorders
• D. Gary Gilliland, USA: To be announced

LUNCH POSTER SESSION SYMPOSIUM Multiple Myeloma and related disorders

• Keneth C. Anderson, USA: To be announced
• Mario Boccadoro, Italy: The role of thalidomide and linelidomide in multiple myeloma
• Joan Blade, Spain: Bortezomib in multiple myeloma
• Bart Barlogie, USA: Tandem SCT for Multiple Myeloma
• John D. Shaughnessy Jr, USA: Multiple myelomas– Dissecting Distinct Biological Entities by Gene Expression Profiling of Plasma Cells and Microenviroment
• Michael Attal , France: Autologous versus allogenic stem cell transplatation for multiple myeloma
• James R Berenson, USA: Treatment strategy for myeloma bone disease

End of the Day: East and West together

• Jorge Cortes,USA: CML and other Myeloproliferative disorders: Current therapy, future trends
• Tamasz Maszi, Hungary: Stem cell transplantation for myeloproliferative disorders
• Keneth C. Andersen, USA: To be announced
• Damir Nemet, Croatia: Stem cell transplantation for multiple myeloma in Croatia
• Peter Černelč, Slovenia: Targeted therapy for multiple myeloma in Slovenia

Tuesday 18. 09. 2007.

SYMPOSIUM ALL

• Dieter Hoelzer, Germany: Current therapy for ALL in adults
• Oliver Ottman, Germany: Tyrosine kinase inhibitors in Ph+ ALL
• Deborah Thomas, USA: Therapy of Burkitt’s and lymphoblastic lymphoma, and Ph+ ALL at MDACC
• Jean Pierre Marrie, France: More intensive chemotherapy for young adults with ALL?
• Susan O’Brien, USA: Novel agents for ALL
• Roel Willemze, Netherland: Alemtuzumab in relapsed ALL

Lunch with Experts
SYMPOSIUM Stem cell transplantation

• Vanderson Rocha, France: Stem cell transplantation for acute leukemia – EBMT survey
• Finn Bo Petersen, USA: MUD transplants for myeloid malignancies
• Dietger Niederwieser, Germany: Reduced intensity conditioning for hematopoetic stem cell transplatation
• Sergio Giralt, USA: Reduced intensity conditioning for myeloid malignancies
• Boris Labar, Croatia: Stem cell transplantation for ALL
• Steven Z. Pavletic, USA: Stem cell transplantation for lymphoproliferative and autoimmune disease
• John Barrett, USA: GvT effect in solid tumors / Techniques to improve and Control Immune reconstitution
• Hans J. Kolb, Germany: Adoptive Immunotherapy in Chimerism - Results and Perspectives

SYMPOSIUM Hodgkin’s lymphoma

• George P. Canellos, USA: To be announced
• Richard T. Hoppe, USA: Radiation therapy for Hodgkin’s lymphoma
• Andreas Engert, Germany: Improving Outcome in High Risk Hodgkin‘s lymphoma
• Anthony Goldstone, UK: To be announced
• Patrice Carde, France: To be announced

End of the day: East and West together

• Alois Gratwohl, Switzerland: Changing trends in stem cell transplantation
• Boris Labar, Croatia: Stem cell transplantation in developing countries
• Volker Diehl, Germany: To be announced
• Ivo Radman, Croatia: Hodgkin’s lymphoma in Croatia

Wednesday 19.09. 2007.

SYMPOSIUM CLL

• Daniel Catovsky, United Kingdom: New diagnostic tools in CLL
• Carlo M. Croce, USA: The new genetics of CLL
• Kanti R. Rai, Long Island, USA: CLL – current treatment approach
• Emilio Monserrat, Spain: First line therapy for Chronic lymphocytic leukemia
• Thomas J. Kipps, USA: Immunotherapy for CLL
• Michael J. Keating, USA: First line therapy with fludarabine, cyclophosphamide and rituximab for CLL
• William Wierda, USA: Gene therapy for CLL

Lunch with experts
SYMPOSIUM non-Hodgkin’s lymphoma

• Peter McLaughlin, USA: Front-line therapy for indolent B-cell lymphoma
• Fernando Cabanillas, Puerto Rico: Therapy for relapsed/refractory indolent lymphoma
• Marek Trneny, Slovakia: PET tailored therapy for NHL
• Michael Pfreundschuh, Germany: Risk adapted treatment of young patients with B-LCL
• Bertrand Coffier, France: To be announced
• Martin Dreyling, Germany: Therapy of Mantle cell Lymphoma
• Julie M. Vose, USA: Therapy for T-cel NHL
• Pier Luigi Zinzani, Italy: Radioimmunotherapy for treatment of non-Hodgkin Lymphoma
• Andrew D. Zelenetz, USA: To be announced
• David G. Maloney, USA: To be announced

End of the day: East and West together

• Michael J. Keating, USA: Therapy for CLL: current approach, future trends
• Branimir Jaksic, Croatia: Therapy for CLL: how to proceed
• Anton Hagenbeek, The Netherlands: Non-Hodgkin’s lymphoma: current treatment approach, future trends
• Igor Aurer, Croatia: Non-Hodgkin’s lymphoma: how to proceed